Michael Platten is a Professor of Neurology and Chairman of the Department of Neurology at the University Hospital in Mannheim at Heidelberg University and Head of the Department of Neuroimmunology and Brain Tumor Immunology at the German Cancer Research Center in Heidelberg He is a Fellow of the European Association of Neurology, Deputy Chair of the German Neurooncology Working Group (NOA) and Co-Coordinator of teh German Cooperative Research Center UNITE Glioblastoma. Michael has received his MD from the University of Bonn, Germany his postdoctoral training at Stanford University and his board certificate in Neurology at the University of Tübingen, Germany. His main scientific focus includes glioma immunogenicity, immune suppression, heterogeneity and personalized treatment strategies. Michael and his team discovered novel pathways involved in immune regulation in gliomas and pioneered the development of therapeutic strategies for the immunotherapy of gliomas and other types of cancer. He is currently leading early multicenter trials testing these strategies. His contributions to brain tumor research have been recognized with the Paul Martini Prize, an ERC Advanced Grant and the German Cancer Award among others. Michael has published more than 350 articles in peer-reviewed journals including Nature, Nature Cancer, Nature Medicine, Science, Cancer Cell, PNAS, JCI, NEJM, Lancet Oncology and JCO and is listed as a Highly Cited Researcher.

Professor Susan Short is Professor of Clinical Oncology and Neuro Oncology in the School of Medicine at the University of Leeds and Consultant Clinical Oncologist at St James’s University Hospital, Leeds. She is an academic oncologist with a research interest in the treatment of adult brain tumours. This includes clinical research in technical radiotherapy developments as well as drug-radiotherapy combinations in early phase clinical studies. She is PI for a portfolio of local and national clinical studies. Her recent laboratory work has included investigation of oncolytic viruses as immune stimulants and adjuvants in gliomas, targeting micro-RNA biology in gliomas and identifying novel approaches to preventing DNA repair following cytotoxic treatments. She has many years of experience in developing and leading major national clinical research groups including as Chair of the UK NCRI Brain Tumour Clinical Study Group, UK NCRI CTRad pre-clinical workstream and is president-elect of the British Neuro Oncology Society. She has been involved in collaborative network activity in EU FP7 (INSERT) as well as national radiotherapy research (CRUK ART-NET and RAD-NET) and national glioma consortia (BRAIN-MATRIX). She currently leads an international consortium addressing application of liquid biomarkers in glioma (BRAIN-LBC).

Manuel Valiente is the Head of the Brain Metastasis Group at CNIO (2015-present). He investigates the biology of brain metastasis in order to challenge this unmet clinical need using his background in Neuroscience (PhD, Instituto de Neurociencias, 2005-2009) and Cancer Biology (Postdoc, MSKCC, 2010-2014).
Specifically, his laboratory studies novel brain metastasis mediators, characterizes the metastasis-associated microenvironment, designs better experimental models and explores novel methods to target brain metastasis, including the frequent impact on brain activity. All these aims consider the brain environment as a critical component to understand the biology of this progression of cancer. Dr. Valiente has co-founded the first National Network of Brain Metastasis (RENACER) in Spain, which is allowing his team to speed up the translation of laboratory findings to the clinic in collaboration with the 18 hospitals associated.
His contributions to brain metastasis research have been recognized with the Banco Sabadell Award, ASPIRE Award, ERC CoG, EMBO YIP, CLIP Award, Beug Foundation’s Prize for Metastasis Research, Bristol-Myers Squibb-MRA Young Investigator Award among others.
He is Board Member and Treasurer of EANO (2024-), Board Member of the Metastasis Research Society (MRS). Other past responsibilities include Chair of the Scientific Committee EANO (2022-2024), ESMO faculty member (CNS Tumours faculty group, 2020-2024), EACR Panel of Reviewers (2022-2024).

Anna Sophie Berghoff is a medical oncologist at the Medical University of Vienna. Here, she head the CNS tumor program including the subversion of International clinical trials as well as translational research projects. Her particular research focus are cancer- immune system interaction in the context of primary an secondary brain tumors.

Emilie Le Rhun joined the Department of Neurosurgery, University Hospital and University of Zurich in June 2020. Before she has been Senior Neuro-Oncologist at the Department of Neurosurgery at the University Hospital Lille, France, since 2007 and at the Cancer Center Oscar Lambret since 2005. She was a member of the EANO Scientific Committee from 2016 to 2020 and is a member of the EANO Guidelines Committee from May 2019, also Member of EANO Guideline Task Force on Glioma; Brain Metastases; Meningioma, Palliative Care. She has been coordinatating the Women in Neuro-Oncology task force /Disparity Committee since its creation in 2019 until 2022. She is also member of the Steering Committee of the EORTC Brain Tumor Group, has been elected Secretary of the EORTC Brain Tumor group in 2020 and leads the EORTC Brain Tumor Group CNS Metastasis Committee. She also serves on various task forces of ESMO and RANO. Her main research interests are brain and leptomeningeal metastasis, including the role of liquid biopsies. She served as the Chairperson of the joint EANO ESMO guideline taskforces on leptomeningeal and brain metastases.

Christian Mawrin is full professor of neuropathology and head of the department of neuropathology at the Otto-von-Guericke University in Magdeburg / Germany. His main research interest is meningioma biology with a focus on translational research combining human tissue analysis with in vitro and in vivo model systems. Recent works center around modeling of recurrent somatic mutations in meningiomas to study their biological function and potential treatment options. Christian Mawrin is secretary general of the german neuropathological society (DGNN) and editor-in chief of Clinical Neuropathology.

Professor of Radiation Oncology and Chair of Academic Unit of Radiation Oncology, Department of Medicine, Surgery and Neuroscience, University of Siena, Si, Italy. Clinical Associate Professor of Radiation Oncology, University of Pittsburgh, PA, USA. Professor Giuseppe Minniti is a radiation oncologist with a specialist research interest in treating adults with primary brain and spine tumors. He completed his medical school training, radiation oncology residency training, and PhD course at University of Rome Sapienza and his fellowship/postdoctoral training in radiation oncology and neuro-oncology at Royal Marsden Hospital NHS Foundation Trust London. Major research interests include optimization of radiation techniques and chemotherapyfor patients with primary and metastatic brain tumors. Professor Minniti serves as a member of the European Association for Neuro-Oncology (EANO), EORTC Brain Tumor Group (treasurer and Chair of Radiotherapy committee), Italian Association of Neuro-Oncology (AINO) and is currently coordinator of CNS tumors of European Society for Medical Oncology (ESMO) Faculty Group. .

Stephen Price is Professor of Neurosurgical Oncology at the University of Cambridge and Co-Director of the Cambridge CRUK-Minderoo Brain Cancer Virtual Institute. His research interest involves the application of advanced MRI and PET imaging to understand the invasive margin of gliomas as well as the impact this invasion has on normal brain function. He has a major developing interest in targeted rehabilitation of cognitive deficits He is the chief investigator for the multi-centre PRaM-GBM study that is qualifying and imaging biomarker to predict sites of tumour progression, the SIND study that explores impact of tumours and surgery on normal brain functioning and the SCARF-BT study – a study looking at the feasibility of a rehabilitation strategy for emotional recognition in brain tumour patients. His current Precision Surgery study is an early surgical study of developing individualised resection targets to direct surgery for glioblastomas.

Prof. Price is the former chair of the Imaging and Technology group of the National Cancer Research Institute’s Brain Tumour study group and is the current neuro-oncology theme lead for the NIHR Brain Injury Medtech Co-operative. He is the lead for the British Neurosurgical Research Group. He has a strong interest in teaching and training as the Clinical Director of Studies for Queens’ College Cambridge, former Training Programme Director for the East of England Neurosurgical Training Programme and is a current member of the UKs Special Advisory Committee on Neurosurgical Training where he takes a lead on clinical academic training.

Dr. Razis studied medicine at Northwestern University, Chicago, IL. She completed a three year medical residency at Beth Israel Medical Center, a six year Honors Program and a three year Oncology Fellowship at New York Medical College/Westchester County Medical Center. She then worked as an Instructor of Medicine in New York Medical College. Upon returning to Greece, she started working as an attending at Hygeia hospital while completing a Ph.D. in Medicine. She is currently appointed as Director in the 3rd Oncology department in Athens, Greece at “Hygeia” Hospital. In the Spring of 2016, Dr. Razis led her practice to the first ever Quality certification by ASCO for an international practice.

Dr. Razis has a strong interest in education, giving several lectures a year and teaching doctors who are in the process of specialization. She has worked voluntarily in the Sudan, in Sri Lanka, in the Honduras, in Zimbabwe, in Rwanda and in Kefalonia, Greece. Her specific interests include Breast Cancer and Neuro-oncology. She actively participates in a number of Medical Associations and cooperative groups, including ASCO, ESMO, EANO, SNO, HeCOG, National Cancer Institute, the Breast International Group, the EORTC Breast Cancer Group, the EORTC Brain Tumor Group, where she is appointed to the Quality assurance subcommittee, and Brain Tumor Funders’ Collaborative Consortium. She has published over 100 papers, has presented several abstracts-posters in international congresses and meetings and has worked on 22 chapters and courses.

Lena Rosenlund has a PhD in Nursing science. Her engagement for patient and caregivers affected by brain tumors started 1997 as a clinical nurse at a neurosurgical ward at the Karolinska university hospital, Stockholm, Sweden. In 2007, she was part of a project to develop a new nursing role in Sweden, contact nurses. As a contact nurse, she was part of the neuro-oncology team and supported patients affected by malignant brain tumor and their caregivers, from the time of diagnosis to death regardless of disease status or clinic involved. Since 2012, she works at the Regional Cancer Centre in Stockholm. Her key interest in research is support to patient and caregivers affected by CNS tumors, psychometrics and metrology in the health sciences, patient involvement and the use of patient-reported measures in clinical practice, improvement work and research. She is an active member of the board of the Swedish national quality registry for brain tumors and implemented patient-reported measures in the registry 2016. She is also part of a national working group for a new real-time registry and to generate online output reports from the national quality registry to reporting clinics. She has joined all the EANO meetings since 2008 and are also member of the EANO Nurses and Allied healthcare professionals since 2021, and the Educational committee since 2022. Lena wishes to contribute to research in neuro-oncology nursing and patient-reported measures and to support other nurses/AHPs to do research, improvement work and network with colleagues around Europe.

Dr Florien Boele is an Associate Professor of Medical Psychology at the University of Leeds. Dr Boele has a background in neuropsychology, and leads a research programme focusing on health-related quality of life and (access to) support in (neuro-)oncology patients and family caregivers. Dr Boele is involved in several clinical trials as patient-centred outcomes expert.
Dr Boele is an active member of EANO, having served on the Scientific Committee (2018-2022), Inclusion and Diversity Committee (2020-2024), the Publishing Committee (2023-2025), and the Nurse & Allied Health Professionals Committee (2021-2025, current chair). She is also actively involved in the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group and in several international initiatives such as the Response Assessment in Neuro Oncology (RANO) – Cares working group, the International Neuro-oncology Caregiver Consortium (INCC), and the Setting International Standards in Analysing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials – IMI (SISAQOL-IMI) consortium.
Dr Boele has served as Associate Editor for Neuro-Oncology Practice and from 2024, joins Neuro-Oncology as Associate Editor. Next to her academic role at the University of Leeds, from 2024 Dr Boele will take up a role at the Dutch Cancer Society to help guide the long-term quality of life research funding strategy.

Norbert Galldiks, MD, is a full Professor of Neurology and Neurooncology at the Medical Faculty of the University Cologne in Germany. Furthermore, he is Leader of the Research Group “Translational Imaging in Neuro-Oncology” at the Institute of Neuroscience and Medicine at the Research Center in Juelich, Germany. He is also a Board of Directors member of the Brain Tumor Center at the University Hospital Cologne, Head of the Outpatient Clinic for patients with brain tumors in the Dept. of Neurology at the University Hospital Cologne, and Chair of the PET Response Assessment in Neuro-Oncology Working Group (PET/RANO). He developed multiple investigator-initiated neuroimaging studies in patients with brain tumors and also served in numerous national and international phase-2 and -3 clinical trials for brain tumor therapy. Additionally, he authored in collaboration with international major societies in the field such as RANO, EANO, EANM, ESMO, and SNMMI guidelines for PET imaging and the clinical management of patients with brain tumors. Currently, he is Associate Editor for the journals Neuro-Oncology Advances and Neuro-Oncology Practice and Editorial Board Member of Neuro-Oncology. Professor Galldiks has multiple publications predominantly focusing on the evaluation of gliomas and brain metastasis using PET, advanced MRI, hybrid PET/MRI, AI, and Radiomics techniques.

Mihaela Lorger is an Associate Professor and Head of the Brain Metastasis Research Group at the University of Leeds in the UK. She completed postdoctoral studies at the University of Zurich in Switzerland and The Scripps Research Institute in California. Her research focuses on the biology of brain metastases, mechanisms underpinning differences in the tumor immune microenvironment between brain metastases and extracranial tumors, resistance to immunotherapy, and development of hematopoietic stem cell gene therapy for brain metastases. The ongoing research integrates studies in pre-clinical models, analysis of human tissue and molecular profiling, and is funded by the Medical Research Council (MRC) UK, Biotechnology and Biological Sciences Research Council (BBSRC) UK, and UK charities. Dr. Lorger is chair of the EANO Educational Committee.

Karin Piil has been working within neuro-oncology since 1994; as a head nurse at the Department of Neurosurgical and currently as a senior researcher at the Department of Oncology at Rigshospitalet, Copenhagen, Denmark.

She holds an international Master of Health Science, Nursing from Deakin University, Melbourne Australia and a Ph.D. on patients with high-grade glioma and the caregivers from the Faculty of Health and Medical Sciences, University of Copenhagen.

Her research has focused on patients’ and relatives´ perspectives on the high-grade glioma trajectory and coping strategies, for example related to the notion on hope and how families and networks can be involved. Current research is inspired from Linné university at Kalmar, Sweden and explores whether systematic and nurse-led family/network conversations can enhance the well-being and social support for the patient.

Karin Piil has a key interest on research on the patient and relative perspectives on the neuro-oncological disease- and treatment course, symptoms such as cognitive challenges, quality of life, family dynamics, bereaved caregivers, patients’ and relatives’ involvement in research processes and decision-making processes among patients with recurrence of malignant brain tumors.

Karin Piil wish to contribute to an even stronger development of an European neuro-oncological research agenda that brings together a multi professional perspective.

Matthias Preusser is a full Professor of Medical Oncology and Head of the Division of Oncology at the Medical University of Vienna. His research focuses on biomarkers and therapy in brain tumours. Recent works focus on the characterization of inflammatory infiltrates and immune checkpoint molecules in various types of brain tumours, the biology of brain metastases and identification of novel treatment options for meningiomas. Dr. Preusser is Chair-elect of the European Organisation for Research and Treatment of Cancer Brain Tumour Group and is leading or actively involved in several international clinical trials in Neuro-oncology.

Prof. Aleksi Sedo, MD, PhD, Professor of Biochemistry and Pathobiochemistry, currently holds the position of Head of the Institute of Biochemistry and Experimental Oncology at the 1st Medical Faculty of Charles University in Prague. His laboratory focuses on the study of the microenvironment of primary and secondary brain tumors with specific emphasis on the function of stromal mesenchymal cells and their role in tumor neovascularization, local immunosuppression and tumor cell invasiveness.
In addition to his academic duties, he serves as Director of the National Cancer Research Institute and as President of the Czech Society of Neuro-Oncology.
Prof. Sedo spent several years as a visiting professor at the Institute of Mutagenesis and Differentiation in Italy, as a visiting scientist at the Institut Curie in France and as a senior scientist in the R&D department of Procter and Gamble in Germany.